Rep. Nancy Pelosi Buys Tempus AI, Inc. (NASDAQ:TEM) Stock

Representative Nancy Pelosi (D-California) recently bought shares of Tempus AI, Inc. (NASDAQ:TEM). In a filing disclosed on January 23rd, the Representative disclosed that they had bought between $50,001 and $100,000 in Tempus AI stock on January 16th.

Representative Nancy Pelosi also recently made the following trade(s):

• Purchased $250,001 – $500,000 in shares of NVIDIA (NASDAQ:NVDA) on 1/16/2026.
• Purchased $500,001 – $1,000,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/16/2026.
• Purchased $500,001 – $1,000,000 in shares of Alphabet (NASDAQ:GOOGL) on 1/16/2026.
• Purchased $100,001 – $250,000 in shares of Vistra (NYSE:VST) on 1/16/2026.
• Sold $5,000,001 – $25,000,000 in shares of Apple (NASDAQ:AAPL) on 12/30/2025.
• Sold $1,000,001 – $5,000,000 in shares of Walt Disney (NYSE:DIS) on 12/30/2025.
• Sold $250,001 – $500,000 in shares of PayPal (NASDAQ:PYPL) on 12/30/2025.
• Sold $1,000,001 – $5,000,000 in shares of Alphabet (NASDAQ:GOOGL) on 12/30/2025.
• Sold $5,000,001 – $25,000,000 in shares of Apple (NASDAQ:AAPL) on 12/24/2025.
• Sold $1,000,001 – $5,000,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/24/2025.

Tempus AI Stock Performance

NASDAQ TEM traded down $1.59 during trading hours on Friday, reaching $58.37. 7,883,470 shares of the company were exchanged, compared to its average volume of 5,200,815. The business’s 50 day simple moving average is $62.35 and its 200-day simple moving average is $73.39. The stock has a market capitalization of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Analysts Set New Price Targets

A number of research firms have weighed in on TEM. JPMorgan Chase & Co. reduced their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Robert W. Baird started coverage on Tempus AI in a research report on Tuesday. They issued an “outperform” rating and a $59.00 target price for the company. Needham & Company LLC raised their price objective on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Morgan Stanley upped their price target on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Mizuho initiated coverage on Tempus AI in a research note on Thursday. They issued an “outperform” rating and a $100.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $85.92.

Institutional Trading of Tempus AI

A number of institutional investors have recently made changes to their positions in TEM. Royal Bank of Canada lifted its stake in Tempus AI by 201.2% during the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after acquiring an additional 17,359 shares during the period. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the first quarter valued at approximately $116,000. Wealth Enhancement Advisory Services LLC grew its position in Tempus AI by 6.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,681 shares of the company’s stock worth $590,000 after acquiring an additional 560 shares during the period. Farther Finance Advisors LLC raised its holdings in Tempus AI by 59.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 884 shares of the company’s stock valued at $56,000 after buying an additional 331 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Tempus AI in the second quarter valued at $2,740,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Activity at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 2,902 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $171,363.10. Following the completion of the sale, the chief accounting officer directly owned 41,159 shares of the company’s stock, valued at $2,430,438.95. This represents a 6.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president owned 126,918 shares of the company’s stock, valued at $7,654,424.58. This trade represents a 7.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 775,159 shares of company stock valued at $50,789,800 in the last quarter. Company insiders own 26.27% of the company’s stock.

About Representative Pelosi

Nancy Pelosi (Democratic Party) is a member of the U.S. House, representing California’s 11th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Pelosi (Democratic Party) is running for re-election to the U.S. House to represent California’s 11th Congressional District. She declared candidacy for the 2026 election.[source]

Pelosi is the first and only woman to serve as speaker of the House. Pelosi was first elected to the U.S. House in a special election in 1987 to represent California’s 5th Congressional District, which she represented until her election to California’s 8th Congressional District in 2012. In 2002, she was elected minority leader, becoming the highest-ranking congresswoman of either party in U.S. history. When Democrats took control of the House in 2007, Pelosi made history again with her election as speaker of the House.

Pelosi was re-elected speaker of the House in 2019, following the 2018 midterm elections. She served in that role until January 3, 2023.

Notable legislation passed during her speakership includes the Affordable Care Act, the American Recovery and Reinvestment Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Lilly Ledbetter Fair Pay Act, and the Don’t Ask, Don’t Tell Repeal Act.

Pelosi is also a prominent Democratic fundraiser, raising more than $700 million for the Democratic Party since becoming a party leader in 2002.

Nancy Pelosi was born in Baltimore, Maryland. Pelosi graduated from the Institute of Notre Dame in 1958. She earned a bachelor’s degree from Trinity College in 1962. Pelosi served as the chair of the California State Democratic Party and the finance chairwoman of the Democratic Senatorial Campaign Committee.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.